Nektar Therapeutics vs Spero Therapeutics
NKTR and SPRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NKTR and SPRO compare
Nektar Therapeutics is the larger company, worth 22 times as much as Spero Therapeutics ($1.3B against $58.2M).
Spero Therapeutics grew revenue faster over the last twelve months (2.5% versus −43.9% for Nektar Therapeutics).
Spero Therapeutics keeps more of each dollar of sales as profit, with a net margin of −71.0% compared with −297% at Nektar Therapeutics.
Nektar Therapeutics scores higher on the StockData Score (9 against 6 for Spero Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NKTR | SPRO |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $58.2M |
| Share price | $37.27 | $1.000 |
| Change, 1 year | −35.4% | −62.4% |
| Change, 5 years | −78.9% | −93.9% |
| Beta (5Y) | 2.06 | 1.12 |
| Employees | 63 | 25 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 23.0× | 1.4× (better) |
| P/B | 1.5× (better) | 74.6× |
| FCF yield | −16.4% | – |
| Growth | ||
| Revenue growth (TTM) | −43.9% | 2.5% (better) |
| Revenue growth, 5Y average | −18.4% | 48.2% (better) |
| Profitability | ||
| Gross margin | 100% | – |
| Operating margin | −254% | −67.3% (better) |
| Net margin | −297% | −71.0% (better) |
| FCF margin | −378% | – |
| Return on equity | −35.1% (better) | −216% |
| Return on invested capital | −441% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.00 (better) | 1.92 |
| Altman Z-score | −0.89 (better) | −6.09 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 105% | 36.9% |
| Held by insiders | 0.46% | 24.6% |
| Insider net buying, 12 months | −$2.2M | −$499K (better) |
| Short interest, % of float | 19.9% | 1.8% |
Go deeper
- NKTR stock overview
- NKTR income statement
- NKTR valuation and score
- SPRO stock overview
- SPRO income statement
- SPRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.